biotech / news / / The Boston Globe
Roche has signed a deal to pay $750 million upfront for Boston-based PathAI.
Roche will acquire PathAI for $750 million upfront, with up to $300 million in milestones.
KEY POINTS
- The acquisition is expected to close in the second half of this year.
- PathAI's AI-powered pathology tools will be integrated with Roche's oncology diagnosis platforms.
- This deal follows an initial 2021 Roche-PathAI partnership later expanded to AI companion diagnostics.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →